Streetbeat News

Revenues

GEVO

Gevo (NASDAQ:GEVO) reported Q2 2024 GAAP EPS of $(0.09), meeting analyst estimates, and sales of $5.260 million, beating the $4.247 million estimate. This represents a 50% increase in losses per share and a 24.12% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 8:47 pm

NGVC

Vitamin Cottage Natural Grocers reported a 9.7% year-over-year increase in Q3 2024 revenue, reaching $309.1 million. The company's earnings per share (EPS) for the quarter were $0.40.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 8:47 pm

INOD

Innodata (NASDAQ:INOD) reported Q2 sales of $32.553 million, surpassing the analyst consensus estimate of $27.593 million by 17.97%. This marks a 65.62% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 8:46 pm

RXT

Rackspace Technology has provided its Q3 2024 financial guidance, forecasting total revenue between $668 million and $680 million, and an adjusted EPS loss between $(0.06) and $(0.08). The guidance is close to analyst estimates, with revenue slightly above and EPS in line with expectations.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 8:46 pm

YELP

Yelp has adjusted its full-year 2024 revenue outlook to a range of $1.41 billion to $1.425 billion, slightly below the previous estimate of $1.427 billion. The company also projects Adjusted EBITDA to be between $325 million and $335 million.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 8:46 pm

AORT

Artrivion projects FY24 revenue growth of 10%-12%, with expected revenue between $388M and $396M, compared to the estimated $391.294M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 8:45 pm

LPRO

Open Lending shares are trading lower after the company reported worse-than-expected Q2 financial results and issued Q3 revenue guidance below estimates.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 8:45 pm

G

Genpact has raised its Q3 revenue guidance to $1.18B-$1.186B, surpassing the $1.16B estimate. The company also increased its FY24 EPS forecast to $3.14-$3.18 from $3.01-$3.04, and its revenue outlook to $4.656B-$4.701B from $4.62B. This reflects strong growth in Digital Operations and Data-Tech-AI segments.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 8:44 pm

COLL

Collegium Pharmaceutical projects its 2024 net product revenues to be between $580 million and $595 million.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 8:44 pm

COLL

Collegium Pharmaceutical (NASDAQ: COLL) reported Q2 2024 adjusted EPS of $1.62, beating the estimate of $1.51. Sales were $145.3M, surpassing the $143.938M estimate and showing a 7.20% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 8:43 pm